Photo: dailymail.co.uk
"Brain Cancer Patients Disheartened as Promising Drug Nixed by NHS"
Patients with brain tumors are disheartened as the NHS rejects vorasidenib, a drug that could potentially slow glioma progression due to concerns over economic data and survival rates.
- The National Institute for Health and Care Excellence has published draft guidance rejecting vorasidenib, a drug for treating low-grade glioma in patients aged 12 and over.
- Vorasidenib aims to slow or halt the growth of neoplasms but was turned down due to uncertainties regarding its economic data and unclear effects on overall survival rates.
- Patients who underwent surgery for glioma now face limited options, as vorasidenibs rejection follows the failure to demonstrate significant improvement in survival rates compared to standard chemotherapy and radiation therapy.
Why It Matters
The rejection of vorasidenib by the NHS highlights ongoing challenges in providing effective treatments for brain tumors. This decision may impact future clinical trials and the development of therapies for mutations associated with glioma.